Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2011 Apr;15(2):99-104.
doi: 10.4103/2230-8210.81938.

Evaluation of efficacy and safety of orlistat in obese patients

Suyog S Jain  1 , Sunita J Ramanand, Jaiprakash B Ramanand, Pramod B Akat, Milind H Patwardhan, Sachin R Joshi
Affiliations

Evaluation of efficacy and safety of orlistat in obese patients

Suyog S Jain et al. Indian J Endocrinol Metab. 2011 Apr.

Abstract

Context: Rapidly rising prevalence of obesity is alarming. Obesity predisposes to co-morbidities like hypertension, type 2 diabetes mellitus, dyslipidemias, thus substantially rising healthcare expenditure. Lifestyle modifications alone have very limited success, necessitating the addition of pharmacotherapy to it.

Objective: Present study was carried out to evaluate the efficacy and safety of orlistat in obese patients.

Materials and methods: Eighty obese (BMI>30) patients according to inclusion and exclusion criteria were randomized into either of the two groups. Group 1 received orlistat 120 mg three times a day and group 2 received placebo three times a day. Weight, waist circumference, BMI, total cholesterol, triglycerides, HDL, LDL were measured at baseline and then at 8(th), 16(th) and 24(th) week. ADR reported by patients were recorded. For safety evaluation various hematological and biochemical parameters were assessed. Z test was used for analysis of data.

Results: Compared to placebo, orlistat caused significant reduction (P<0.05) in weight (4.65 kg vs 2.5 kg; orlistat vs placebo, respectively), BMI (1.91 kg/m(2) vs 0.64 kg/m(2)) and waist circumference (4.84 cm vs 2 cm), cholesterol (10.68 mg vs 6.18 mg) and LDL level (5.87 mg vs 2.33 mg). In the orlistat group, the GI side effects like loose stools, oily stools/spotting, abdominal pain and fecal urgency were observed.

Conclusion: Orlistat is an effective and well-tolerated antiobesity drug, which can be employed as an adjunct to therapeutic lifestyle changes to achieve and maintain optimal weight.

Keywords: Antiobesity agents; obesity; orlistat; weight loss.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest: None declared.

Figures

Figure 1
Figure 1
Comparison between effect of orlistat and placebo on efficacy parameters at 24 weeks (*P<0.05)
See this image and copyright information in PMC

References

    1. Spiegelman BM, Flier JS. Obesity and the regulation of energy balance. Cell. 2001;104:531–43. - PubMed
    1. Misra A, Khurana L. Obesity and the metabolic syndrome in developing countries. J Clin Endocrinol Metab. 2008;93:S9–30. - PubMed
    1. Christensen R, Kristensen PK, Bartels EM, Bliddal H, Astrup A. Efficacy and safety of weight- loss drug rimonabant: A meta-analysis of randomized trials. Lancet. 2007;370:1706–13. - PubMed
    1. Padwal RS, Majumdar SR. Drug treatments for obesity: Orlistat, sibutramine, and rimonabant. Lancet. 2007;369:71–7. - PubMed
    1. Finer N, James WP, Kopelman PG, Lean ME, Williams G. One year treatment of obesity: A randomized, double blind, placebo-controlled, multicentre study of orlistat, a gastrointestinal lipase inhibitor. Int J Obes Relat Metab Disord. 2000;24:306–13. - PubMed